Company / SG&A Expense
Progyny SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$147.1M
FY2025
5-year range
$59.6M / $147.1M
FY2021-FY2025
Trend
+20.6%
vs FY2024
Sector context
#115 of 152
Health Care
What the data says
Progyny's sg&a expense of $147M is lower than 76% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 8 consecutive years, from $14M in FY2017 to $147M in FY2025.
Based on SEC 10-K filings.
$147M in FY2025 with a 5-year CAGR of +25.8%.
Increased from $117M to $147M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +14.4%
- 5-Year CAGR
- +25.8%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 152This company $147.1M Sector average $182.7B
▼
-99.9% below sector average
Key checks
Key Insights
- Progyny's sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +25.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 20.6% year-over-year.
- Ranks #115 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $147.1M | +20.6% |
| FY2024 | $122.0M | +4.1% |
| FY2023 | $117.1M | +19.1% |
| FY2022 | $98.3M | +64.9% |
| FY2021 | $59.6M | +27.6% |
| FY2020 | $46.7M | +95.2% |
| FY2019 | $23.9M | +53.4% |
| FY2018 | $15.6M | +10.3% |
| FY2017 | $14.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026